| Coffeyville Regional Medical Center Inc | |
|
1400 W 4th St Ste 100 Coffeyville KS 67337-3306 | |
| (620) 688-6566 | |
| Not Available |
| Full Name | Coffeyville Regional Medical Center Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1400 W 4th St, Coffeyville, Kansas |
| Authorized Official Name and Position | Brian H Lawrence (CEO) |
| Authorized Official Contact | 6202511200 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Coffeyville Regional Medical Center Inc 1400 W 4th St Coffeyville KS 67337-3306 Ph: (620) 251-1200 | Coffeyville Regional Medical Center Inc 1400 W 4th St Ste 100 Coffeyville KS 67337-3306 Ph: (620) 688-6566 |
| NPI Number | 1053862805 |
|---|---|
| Provider Enumeration Date | 10/17/2016 |
| Last Update Date | 03/17/2023 |
| Medicare PECOS PAC ID | 9032108865 |
|---|---|
| Medicare Enrollment ID | O20161118000585 |
News Archive
The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).
Scientific papers suggesting that smokers are less likely to fall ill with covid-19 are being discredited as links to the tobacco industry, reveals an investigation by The BMJ today.
A new study of U.S. maternal outcomes after vaginal and cesarean deliveries published in the May 2010 issue of Anesthesia & Analgesia, a peer-reviewed academic journal, shows that between 1995 and 2004, postpartum hemorrhage (excessive blood loss after delivery) increased 28% in prevalence. Postpartum hemorrhage is one of today's most common complications for delivering mothers that according to the study, "markedly increases the odds of in-hospital mortality" and causes 19% of in-hospital maternal deaths.
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053862805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QR1300X | Clinic/center - Rural Health | (* (Not Available)) | Primary |
News Archive
The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).
Scientific papers suggesting that smokers are less likely to fall ill with covid-19 are being discredited as links to the tobacco industry, reveals an investigation by The BMJ today.
A new study of U.S. maternal outcomes after vaginal and cesarean deliveries published in the May 2010 issue of Anesthesia & Analgesia, a peer-reviewed academic journal, shows that between 1995 and 2004, postpartum hemorrhage (excessive blood loss after delivery) increased 28% in prevalence. Postpartum hemorrhage is one of today's most common complications for delivering mothers that according to the study, "markedly increases the odds of in-hospital mortality" and causes 19% of in-hospital maternal deaths.
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.
› Verified 2 days ago
Chc/sek's Field Kindley Student Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1110 W 8th St, Coffeyville, KS 67337 Phone: 620-252-1798 Fax: 620-252-1799 | |
Coffeyville Family Practice Clinic, P.a. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 209 W 7th St, Coffeyville, KS 67337 Phone: 620-251-1100 Fax: 620-251-7466 | |
Coffeyville Doctors Clinic P A Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 801 W 8th St, Coffeyville, KS 67337 Phone: 620-251-7500 Fax: 620-252-1715 | |
Southeast Kansas Medical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1501 W 4th St, Coffeyville, KS 67337 Phone: 620-251-2400 Fax: 620-251-1619 | |
Coffeyville Regional Medical Center, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1400 W 4th St, Coffeyville, KS 67337 Phone: 620-688-6566 Fax: 620-688-6577 | |
Community Health Center Of Southeast Kansas, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 102 S Cline, Coffeyville, KS 67337 Phone: 620-252-6989 Fax: 620-251-3691 |